Jim Birchenough
Stock Analyst at Wells Fargo
(2.83)
# 1,907
Out of 5,090 analysts
30
Total ratings
52.63%
Success rate
37.79%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jim Birchenough
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SGMO Sangamo Therapeutics | Maintains: Equal-Weight | $3 → $2 | $0.50 | +303.31% | 2 | Dec 31, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Equal-Weight | $55 → $70 | $56.88 | +23.07% | 3 | Feb 22, 2024 | |
| ZYME Zymeworks | Maintains: Overweight | $56 → $48 | $26.69 | +79.84% | 3 | Feb 9, 2022 | |
| FATE Fate Therapeutics | Maintains: Overweight | $84 → $130 | $1.08 | +11,937.04% | 4 | Mar 4, 2021 | |
| PGEN Precigen | Initiates: Overweight | $14 | $3.60 | +288.89% | 1 | Feb 22, 2021 | |
| MRNA Moderna | Maintains: Equal-Weight | $129 → $145 | $27.70 | +423.47% | 2 | Feb 1, 2021 | |
| GILD Gilead Sciences | Maintains: Equal-Weight | $69 → $63 | $121.22 | -48.03% | 5 | Oct 29, 2020 | |
| RNA Avidity Biosciences | Initiates: Overweight | n/a | $71.63 | - | 1 | Jul 7, 2020 | |
| QURE uniQure | Downgrades: Equal-Weight | $56 | $21.33 | +162.54% | 3 | Jun 25, 2020 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Overweight | $734 | $718.36 | +2.18% | 2 | May 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $300 → $180 | $6.25 | +2,780.00% | 1 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $33 | $7.92 | +316.67% | 3 | Jun 28, 2018 |
Sangamo Therapeutics
Dec 31, 2024
Maintains: Equal-Weight
Price Target: $3 → $2
Current: $0.50
Upside: +303.31%
CRISPR Therapeutics AG
Feb 22, 2024
Maintains: Equal-Weight
Price Target: $55 → $70
Current: $56.88
Upside: +23.07%
Zymeworks
Feb 9, 2022
Maintains: Overweight
Price Target: $56 → $48
Current: $26.69
Upside: +79.84%
Fate Therapeutics
Mar 4, 2021
Maintains: Overweight
Price Target: $84 → $130
Current: $1.08
Upside: +11,937.04%
Precigen
Feb 22, 2021
Initiates: Overweight
Price Target: $14
Current: $3.60
Upside: +288.89%
Moderna
Feb 1, 2021
Maintains: Equal-Weight
Price Target: $129 → $145
Current: $27.70
Upside: +423.47%
Gilead Sciences
Oct 29, 2020
Maintains: Equal-Weight
Price Target: $69 → $63
Current: $121.22
Upside: -48.03%
Avidity Biosciences
Jul 7, 2020
Initiates: Overweight
Price Target: n/a
Current: $71.63
Upside: -
uniQure
Jun 25, 2020
Downgrades: Equal-Weight
Price Target: $56
Current: $21.33
Upside: +162.54%
Regeneron Pharmaceuticals
May 26, 2020
Upgrades: Overweight
Price Target: $734
Current: $718.36
Upside: +2.18%
Mar 13, 2020
Maintains: Overweight
Price Target: $300 → $180
Current: $6.25
Upside: +2,780.00%
Jun 28, 2018
Maintains: Outperform
Price Target: $31 → $33
Current: $7.92
Upside: +316.67%